Skip to content
Screener

Annexon ANNX Current ratio

Current ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.3×-1.3×
Omeros logo
OmerosOMER
+1.9×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
22.1×+13.0×
Jade Biosciences logo
Jade BiosciencesJBIO
14.3×-17.7×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
29.3×+13.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
8.4×-1.4×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$886.39M+244%
Enterprise value$736.61M+381%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Annexon’s reported figures.

Based on the most recent quarter.

The source filing: Annexon’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211931

FAQ

What is Annexon's current ratio?
Annexon (ANNX) reported current ratio of 6.4× in Q1 2026.
How has Annexon's current ratio changed year-over-year?
Annexon's current ratio decreased by 20.5% year-over-year, from 8× to 6.4×.
What is the long-term trend for Annexon's current ratio?
Over 5 years (2020 to 2025), Annexon's current ratio has grown at a -29.8% compound annual growth rate (CAGR), from 33.3× to 5.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Annexon's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude